Cellerant gets additional funding from BARDA
The additional funding is expected to support Cellerant’s CLT-008 development strategy to expand its current clinical trials, process development and manufacturing activities and to fund additional nonclinical studies
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.